Efficacy and safety of botulinum toxin type A for treatment of Frey's syndrome: evidence from 22 published articles
In conclusion, our study supports that BTXA produces meaningful benefits on the treatment of patients with FS. However, owing to lack of strong evidence, future studies with well‐designed inclusion criteria and multicenter randomized controlled trials are needed to give more credible evidence, if possible.
Botulinum toxin type A produces meaningful benefits on the treatment of patients with Frey's syndrome. However, owing to a lack of strong evidence, future studies with well‐designed inclusion criteria and multicenter randomized controlled trials are needed to give more credible evidence, if possible.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Shang Xie, Kan Wang, Tao Xu, Xue‐Sheng Guo, Xiao‐Feng Shan, Zhi‐Gang Cai Tags: Original Research Source Type: research
More News: Botox | Cancer | Cancer & Oncology | Databases & Libraries | Science | Statistics | Study